klc-2 Antibody

What is KLC2 and why is it an important target for antibody-based research?

KLC2 (Kinesin Light Chain 2) is a microtubule-associated force-producing protein component that plays a crucial role in organelle transport within cells. The light chain functions primarily in coupling cargo to the kinesin heavy chain or modulating its ATPase activity. Through binding with proteins such as PLEKHM2 and ARL8B, KLC2 recruits kinesin-1 to lysosomes and directs lysosomal movement toward microtubule plus ends . Given its fundamental role in cellular transport mechanisms, KLC2 has become an important target for researchers studying intracellular trafficking, neurodegenerative disorders, and various cellular functions dependent on proper organelle positioning.

What are the key differences between the various commercially available KLC2 antibodies?

KLC2 antibodies differ primarily in their immunogen target regions, validated applications, and species reactivity profiles. Most commercial antibodies are rabbit polyclonal preparations targeting different epitopes of the KLC2 protein:

When selecting an antibody, researchers should consider which region of KLC2 they wish to target, the specific application requirements, and whether posttranslational modifications might affect epitope recognition .

How should KLC2 antibodies be stored and handled to maintain optimal activity?

For optimal preservation of KLC2 antibody activity, adhere to these storage and handling guidelines:

• Short-term storage (up to 1 week): Store at 2-8°C in the original container

• Long-term storage: Maintain at -20°C, avoiding repeated freeze-thaw cycles

• Do not freeze antibodies in glycerol-containing formulations

• When working with the antibody, keep it on ice or at 4°C

• Avoid vortexing or vigorous shaking to prevent protein denaturation

• Centrifuge briefly after thawing to collect all liquid at the bottom of the tube

• Consider preparing small working aliquots to minimize freeze-thaw cycles

Most KLC2 antibodies demonstrate stability for approximately 12 months when stored properly, though specific formulations may have different shelf-life recommendations .

What are the optimal conditions for using KLC2 antibodies in Western blot applications?

The optimal Western blot protocol for KLC2 antibodies requires careful consideration of sample preparation, protein loading, and detection methods:

Recommended Protocol:

• Sample preparation: Lyse cells in RIPA or NP-40 buffer containing protease inhibitors

• Protein loading: 15-50 μg of total protein per lane is typically sufficient

• Gel percentage: Use 8-10% SDS-PAGE (KLC2 predicted band size: 69 kDa)

• Transfer conditions: Wet transfer at 100V for 1 hour or 30V overnight

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody dilution:

  • For ab254848: 0.4 μg/mL

  • For NBP1-46841: 1:2000-1:10000

  • For 102-11465: 1:1000

• Incubation: Overnight at 4°C with gentle rocking

• Detection system: HRP-conjugated secondary antibody with chemiluminescence

To confirm specificity, include positive controls (e.g., lysates from NIH/3T3, U-251 MG, or HeLa cells) and consider siRNA knockdown controls to validate band identity .

How should researchers optimize immunohistochemistry protocols for KLC2 detection in tissue samples?

For optimal KLC2 detection in tissue samples via immunohistochemistry, researchers should follow these guidelines:

• Fixation: 10% neutral buffered formalin (24-48 hours)

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody dilution:

  • For ab254848: 1:500

  • For HPA040434: 1:1000-1:2500

  • For 102-11465: Empirically determined for each tissue type

• Incubation time: Overnight at 4°C for optimal sensitivity

• Detection system: Polymer-HRP system followed by DAB visualization

• Counterstaining: Hematoxylin for nuclear visualization

For validation, consider using multiple tissue types. Published data shows successful KLC2 detection in human prostate, testis, fallopian tube, cerebral cortex, and uterine tissues .

What approaches can be used to validate KLC2 antibody specificity in experimental systems?

Validating KLC2 antibody specificity is critical for ensuring reliable experimental results. Implement these validation approaches:

• siRNA knockdown: Transfect cells with KLC2-targeting siRNA and confirm reduction in signal. Published data shows effective validation using U-138 MG cells with two distinct siRNA probes .

• Overexpression systems: Compare signal in cells transfected with KLC2 expression vector versus empty vector controls.

• Peptide competition: Pre-incubate the antibody with immunizing peptide before application to samples.

• Multi-antibody comparison: Test multiple antibodies targeting different epitopes of KLC2 (e.g., N-terminal versus C-terminal regions).

• Cross-species reactivity check: Verify expected band patterns across species based on sequence conservation.

• Mass spectrometry confirmation: Immunoprecipitate KLC2 and confirm protein identity via mass spectrometry.

• Genetic models: If available, test antibody in KLC2 knockout/knockdown models or tissues.

Implementing at least three of these validation approaches significantly enhances confidence in antibody specificity .

How can KLC2 phosphorylation states be detected and what signaling pathways regulate this modification?

KLC2 phosphorylation is a dynamic regulatory mechanism that affects cargo binding. To detect and study these phosphorylation states:

Detection Methods:

Regulatory Pathways:
KLC2 phosphorylation is regulated through several interconnected pathways:

• LMTK2 pathway: LMTK2 promotes KLC2 dephosphorylation through PP1C activation

• GSK3β pathway: GSK3β directly phosphorylates KLC2, inhibiting cargo binding

• PP1C regulation: Dephosphorylates KLC2, enhancing cargo binding

Research has demonstrated that LMTK2 overexpression decreases KLC2 phosphorylation, while LMTK2 knockdown increases it. This effect is abolished by tautomycetin (a PP1C inhibitor), confirming PP1C involvement in the pathway .

What experimental approaches can assess KLC2-cargo interactions and how are they affected by phosphorylation?

Studying KLC2-cargo interactions requires specialized techniques that can detect protein-protein associations under various conditions:

Experimental Approaches:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate KLC2 using validated antibodies (e.g., NBP1-46841 at 3 μg/mg lysate)

  • Detect associated cargo proteins (e.g., Smad2) by Western blot

  • Compare binding under different phosphorylation conditions

• Proximity ligation assay (PLA):

  • Visualize protein interactions in situ with single-molecule resolution

  • Quantify changes in interaction frequency under different conditions

• FRET/BRET analysis:

  • Monitor real-time interactions in living cells

  • Assess dynamic changes following stimuli that alter phosphorylation

• Phosphorylation modification:

  • Use phosphomimetic (S→D/E) or phospho-deficient (S→A) KLC2 mutants

  • Compare cargo binding between mutants and wild-type protein

  • Treat cells with kinase inhibitors (e.g., GSK3β inhibitors) or phosphatase inhibitors (e.g., tautomycetin)

Research shows that KLC2 phosphorylation regulated by LMTK2 directly affects its binding to Smad2, with increased phosphorylation typically reducing cargo association .

How can KLC2 antibodies be utilized in studying neurodegenerative diseases and intracellular transport defects?

KLC2 is particularly relevant to neurodegenerative disease research due to its critical role in axonal transport. Researchers can employ KLC2 antibodies in these advanced applications:

• Axonal transport assays:

  • Track movement of fluorescently labeled organelles in primary neurons

  • Correlate transport defects with KLC2 localization and modification states

  • Use ICC/IF with ab254848 (4μg/ml) to visualize KLC2 distribution along axons

• Brain tissue analysis:

  • Perform IHC in normal versus diseased brain tissues (e.g., cerebral cortex)

  • Quantify KLC2 expression/localization changes using antibodies validated for neuronal tissues

  • Combine with markers for specific cargoes (e.g., mitochondria, lysosomes)

• Patient-derived models:

  • Compare KLC2-cargo interactions in iPSC-derived neurons from patients versus controls

  • Assess phosphorylation status and transport efficiency

• Therapeutic screening:

  • Use KLC2 antibodies to evaluate effects of potential drugs on restoring normal transport

  • Monitor changes in KLC2 phosphorylation and cargo binding following treatment

• Animal model validation:

  • Verify KLC2 expression patterns in transgenic disease models

  • Correlate transport defects with disease progression

The immunohistochemistry analysis of human cerebral cortex tissue using ab254848 provides a foundation for these neurodegeneration studies .

What are the most common issues encountered when using KLC2 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with KLC2 antibodies. Here are solutions to the most common issues:

For challenging applications, consider using a combination of antibodies recognizing different epitopes, as demonstrated with NBP1-46841 and BL9877 for immunoprecipitation studies .

How can researchers optimize antibody dilutions and incubation conditions for different experimental systems?

Optimizing antibody conditions is essential for achieving reliable, reproducible results. Follow this systematic approach:

Antibody Titration Strategy:

• Initial dilution ranges based on application:

  • Western blot: Start with manufacturer recommendations (e.g., 0.04-0.4 μg/mL for ab254848, 1:2000-1:10000 for NBP1-46841)

  • IHC-P: Begin with 1:500 for ab254848 or 1:1000-1:2500 for HPA040434

  • ICC/IF: Start with 4 μg/mL for ab254848 or 0.25-2 μg/mL for HPA040434

  • IP: 3 μg/mg lysate for NBP1-46841

• Perform checkerboard titration:

  • Test 3-5 different antibody concentrations

  • Simultaneously vary incubation times (1h, 2h, overnight)

  • Evaluate signal-to-noise ratio for each condition

• Temperature optimization:

  • Compare room temperature versus 4°C incubation

  • For IHC/ICC, overnight incubation at 4°C often yields best results

  • For WB, some antibodies perform better at room temperature for 2h

• Cell/tissue-specific adjustments:

  • Different cell lines may require modified conditions (e.g., NIH/3T3 vs. U-251 MG)

  • Increase antibody concentration for tissues with fixation-induced epitope masking

  • Decrease concentration for overexpression systems

• Documentation and standardization:

  • Record optimal conditions for each experimental system

  • Maintain consistent lot numbers when possible

  • Include validated positive controls in each experiment

Published data demonstrates successful use of ab254848 at 0.4 μg/mL for Western blot of various cell lines and at 1:500 for IHC of multiple human tissues .

How do differences in KLC2 expression and phosphorylation correlate with specific cellular functions or disease states?

KLC2 expression and phosphorylation variations have significant implications for cellular function and disease pathology:

KLC2 in Normal Physiology:

• Maintains proper organelle distribution, particularly lysosomes

• Facilitates axonal transport in neurons

• Regulates cargo specificity through phosphorylation-dependent mechanisms

• Interacts with signaling mediators such as Smad2

Pathological Implications:

• Neurodegeneration:

  • Altered KLC2 phosphorylation can disrupt axonal transport

  • Potential contributor to aggregation of disease-associated proteins

  • Implicated in lysosomal dysfunction mechanisms

• Cancer:

  • LMTK2, a regulator of KLC2 phosphorylation, is a prostate cancer susceptibility gene

  • Altered KLC2-mediated transport may affect cancer cell migration and invasion

  • KLC2 expression detected in various cancer cell lines (e.g., MCF-7, U-138 MG)

• Cellular Stress Responses:

  • Phosphorylation changes respond to cellular stress signals

  • May redirect transport priorities under pathological conditions

When interpreting KLC2 data, researchers should consider both expression levels and phosphorylation state, as the latter significantly impacts function even when total protein levels remain constant .

What experimental controls are essential when designing studies involving KLC2 antibodies?

Robust experimental design requires inclusion of appropriate controls for KLC2 antibody-based studies:

Essential Controls for KLC2 Antibody Experiments:

• Antibody validation controls:

  • Knockdown validation: siRNA-treated samples (demonstrated with U-138 MG cells)

  • Loading controls: GAPDH or similar housekeeping proteins for normalization

  • Negative control antibodies: Isotype-matched irrelevant antibodies to assess non-specific binding

• Sample-specific controls:

  • Positive tissue/cell controls: Samples with verified KLC2 expression (e.g., cerebral cortex, testis, HeLa cells)

  • Negative tissue controls: Samples with minimal KLC2 expression or epitopes blocked by competing peptide

  • Processing controls: Samples processed identically except for primary antibody omission

• Functional controls:

  • Phosphorylation studies: Phosphatase-treated samples as dephosphorylation controls

  • Kinase inhibition: GSK3β inhibitor-treated samples to verify phosphorylation pathways

  • PP1C inhibition: Tautomycetin-treated samples to confirm phosphatase involvement

• Application-specific controls:

  • IP experiments: IgG control immunoprecipitation to identify non-specific binding

  • IHC/ICC: Serial sections with primary antibody omission

  • Flow cytometry: Fluorescence-minus-one (FMO) controls

Published data demonstrates the value of these controls, particularly the use of siRNA knockdown and phosphatase inhibitor controls for understanding KLC2 regulation .

How can researchers integrate KLC2 antibody data with other experimental approaches to build comprehensive understanding of intracellular transport mechanisms?

Developing a complete picture of intracellular transport requires integration of multiple experimental approaches alongside KLC2 antibody data:

Integrative Research Strategy:

• Multi-technique structural analysis:

  • Combine immunolocalization data (ICC/IF) with super-resolution microscopy

  • Correlate with electron microscopy for ultrastructural context

  • Use FRET/BRET to assess protein-protein interactions in real-time

• Functional transport assays:

  • Live-cell imaging of cargo movement in KLC2-manipulated systems

  • Quantify transport parameters (velocity, run length, frequency)

  • Correlate with KLC2 phosphorylation status determined by antibody-based assays

• Multi-omics integration:

  • Combine proteomics (KLC2 interactome) with phosphoproteomics

  • Integrate transcriptomics to identify regulatory networks

  • Correlate with functional readouts from transport assays

• Physiological context:

  • Apply findings from cell models to tissue and organismal systems

  • Assess impact on cellular functions beyond transport (signaling, metabolism)

  • Connect to disease phenotypes in patient samples or animal models

• Pathway analysis:

  • Study KLC2 in context of known regulatory pathways (LMTK2, GSK3β, PP1C)

  • Investigate effects of perturbations on downstream cellular processes

  • Develop computational models integrating experimental data

This integrated approach allows researchers to connect structural observations (antibody localization) with functional outcomes (cargo movement) and molecular mechanisms (phosphorylation), building a comprehensive understanding of KLC2's role in intracellular transport .